נורווסק 10 מג טבליות ישראל - עברית - Ministry of Health

נורווסק 10 מג טבליות

pfizer pfe pharmaceuticals israel ltd - amlodipine as besylate - טבליה - amlodipine as besylate 10 mg - amlodipine - amlodipine - mild to moderate hypertension. vasospastic angina ( prinzmetal's or variant angina). chronic stable angina.

ליפיטור 80 מג ישראל - עברית - Ministry of Health

ליפיטור 80 מג

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - טבליות מצופות פילם - atorvastatin as calcium 80 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

ליפיטור 10 מג ישראל - עברית - Ministry of Health

ליפיטור 10 מג

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - טבליות מצופות פילם - atorvastatin as calcium 10 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

ליפיטור 20 מג ישראל - עברית - Ministry of Health

ליפיטור 20 מג

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - טבליות מצופות פילם - atorvastatin as calcium 20 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

הרמונט ישראל - עברית - Ministry of Health

הרמונט

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליות מצופות - ethinylestradiol 0.020 mg; gestodene 0.075 mg - gestodene and estrogen - gestodene and estrogen - contraceptive.

מינס ישראל - עברית - Ministry of Health

מינס

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליות מצופות פילם - ethinylestradiol 0.015 mg; gestodene 0.06 mg - gestodene and estrogen - gestodene and estrogen - contraceptive.

מינולט ישראל - עברית - Ministry of Health

מינולט

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליה - gestodene 0.075 mg; ethinylestradiol 0.030 mg - ethinylestradiol - ethinylestradiol - contraception.

אזניל כמוסות ישראל - עברית - Ministry of Health

אזניל כמוסות

pfizer pfe pharmaceuticals israel ltd - azithromycin as dihydrate - קפסולות - azithromycin as dihydrate 250 mg - azithromycin - azithromycin - infections caused by susceptible organisms in lower respiratory tract including bronchitis and pneumonia, skin and soft tissue infections, otitis media, upper respiratory tract infections including sinusitis and pharyngitis, tonsilitis, also in the treatment of uncomplicated genital infections due to chlamydia trachomatis.

אזניל 200 מג5 מל תרחיף ישראל - עברית - Ministry of Health

אזניל 200 מג5 מל תרחיף

pfizer pfe pharmaceuticals israel ltd - azithromycin as dihydrate - אבקה להכנת תרחיף - azithromycin as dihydrate 200 mg / 5 ml - azithromycin - azithromycin - infections caused by susceptible organisms in lower respiratory tract including bronchitis and pneumonia, skin and soft tissue infections, otitis media, upper respiratory tract infections including sinusitis and pharyngitis, tonsilitis, also in the treatment of uncomplicated genital infections due to chlamydia trachomatis.

ויפנד 50 מג טבליות מצופות ישראל - עברית - Ministry of Health

ויפנד 50 מג טבליות מצופות

pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 50 mg - voriconazole - voriconazole - treatment of: invasive aspergillosis, fluconazole-resistant serious invasive candida infections (including c. krusei) serious fungal infections caused by scedosporium spp. and fusarium spp. vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.